SCYNEXIS, Inc. Announces Exclusive Licensing Deal for the Treatment of Canine Dry Eye
Published: Sep 04, 2012
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--SCYNEXIS, Inc. announced today that it has entered into an exclusive license agreement with Dechra Pharmaceuticals PLC (LSE:DPH) for the development and commercialization of SCY-641 for the treatment of canine keratoconjunctivitis sicca (KCS). SCY-641, a cyclosporine derivative, is the first partnered compound from the SCYNEXIS proprietary cyclophilin inhibitor platform, which includes SCY-635, a clinical candidate for the treatment of Hepatitis C (HCV).